Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIVATED-4-PC study of AZD6621 in metastatic castration-resistant prostate cancer
jRCT2031250544Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2026
- Modality
- Small Molecules
01
Overview
Open-label trial of selumetinib in prostate cancer (PCa) (2 arms), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events, adverse events of special interest, and serious adverse events, Number of participants with dose-limiting toxicity and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
selumetinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031250544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250544.